Home › Funds › Sanofi › TRAX

Sanofi position in TRAX

FIRST TRACKS BIOTHERAPEUTICS · Health Care

Sanofi reported holding 821,917 shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$29.1M, representing 4.62% of its reported portfolio and ranking #8 among its reported holdings. Sanofi has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)821.92K sh
Reported value held$29.13M
Portfolio Weight4.62%
First reportedQ2 2026
Last changeHold
Updated2026-11-05

Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR

How Sanofi's TRAX position evolved

Sanofi first disclosed a stake in TRAX in Q2 2026 at 821,917 shares (US$16.5M). The position peaked in Q3 2026 at 821,917 shares, worth US$29.1M. Across 2 filings, Sanofi held the position steady without any share-count change. The most recent filing (Q3 2026) shows 821,917 shares valued at US$29.1M.

Quarter by quarter

QuarterSharesValueChange
Q2 2026 821.92K $16.54M New
Q3 2026 821.92K $29.13M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TRAX and 13F data

TRAX (FIRST TRACKS BIOTHERAPEUTICS) is a Health Care company. 156 other funds we track also report a position in TRAX — the largest reported positions include EcoR1 Capital, LLC (US$63.9M), TCG Crossover Management, LLC (US$58.3M), Affinity Asset Advisors, LLC (US$40.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TRAX

All TRAX fund holders →

FAQ

How long has Sanofi held TRAX?

Sanofi has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Sanofi's current position in TRAX?

As of Q3 2026, Sanofi holds 821.92K shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS), valued at $29.13M, representing 4.62% of its reported portfolio and ranking #8.

Has Sanofi been buying or selling TRAX?

In the latest 13F filing (Q3 2026), Sanofi held unchanged its position in TRAX. The position peaked in Q3 2026 at 821.92K shares.

Which other funds hold TRAX?

Other major institutional holders of TRAX include EcoR1 Capital, LLC, TCG Crossover Management, LLC, Affinity Asset Advisors, LLC, among 156 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.